Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
140.98
+0.43 (0.31%)
At close: Jan 21, 2025, 4:00 PM
141.55
+0.57 (0.40%)
After-hours: Jan 21, 2025, 6:47 PM EST
Biogen Employees
Biogen had 7,570 employees as of December 31, 2023. The number of employees decreased by 1,155 or -13.24% compared to the previous year.
Employees
7,570
Change (1Y)
-1,155
Growth (1Y)
-13.24%
Revenue / Employee
$1,269,155
Profits / Employee
$213,369
Market Cap
20.54B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | 7,400 | -400 | -5.13% |
Dec 31, 2018 | 7,800 | 500 | 6.85% |
Dec 31, 2017 | 7,300 | -100 | -1.35% |
Dec 31, 2016 | 7,400 | 50 | 0.68% |
Dec 31, 2015 | 7,350 | -200 | -2.65% |
Dec 31, 2014 | 7,550 | 700 | 10.22% |
Dec 31, 2013 | 6,850 | 900 | 15.13% |
Dec 31, 2012 | 5,950 | 950 | 19.00% |
Dec 31, 2011 | 5,000 | 150 | 3.09% |
Dec 31, 2010 | 4,850 | 100 | 2.11% |
Dec 31, 2009 | 4,750 | 50 | 1.06% |
Dec 31, 2008 | 4,700 | 400 | 9.30% |
Dec 31, 2007 | 4,300 | 550 | 14.67% |
Dec 31, 2006 | 3,750 | 410 | 12.28% |
Dec 31, 2005 | 3,340 | -926 | -21.71% |
Dec 31, 2004 | 4,266 | 539 | 14.46% |
Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
Jan 31, 2003 | 995 | 303 | 43.79% |
Jan 31, 2002 | 692 | 199 | 40.37% |
Jan 31, 2001 | 493 | 86 | 21.13% |
Jan 31, 2000 | 407 | 42 | 11.51% |
Jan 31, 1999 | 365 | 26 | 7.67% |
Dec 31, 1997 | 339 | 71 | 26.49% |
Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
BIIB News
- 6 days ago - Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript) - Seeking Alpha
- 7 days ago - Biogen CEO sees no burning need for more acquisitions - Reuters
- 8 days ago - FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease - GlobeNewsWire
- 8 days ago - Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid - Investopedia
- 8 days ago - Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen - Barrons
- 11 days ago - Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Business Wire
- 11 days ago - Biogen proposes to buy remaining stake in Sage in $442 million deal - Reuters
- 13 days ago - Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer - Business Wire